Nasdaq: ORMP/Biotechnology
Oramed Pharmaceuticals Inc.
New York, NY, United States
Company overview
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
This profile is for informational purposes only and is not investment advice. Company information may change after the verification date.